These human antibodies target the protein, protogenin, to reduce growth of medulloblastomas. Medulloblastoma is one of the most prevalent forms of pediatric brain cancer, accounting for up to 20% of cases. Currently, medulloblastoma is treated with a combination of surgical removal, radiation therapy, and chemotherapy. With these treatment options, recurrence rates amongst children are 30% and recurrence is typically fatal. Immunotherapy is a promising form of treatment that manipulates the immune system to fight cancer. Although it has been successfully applied to other forms including bladder and lung cancer, immunotherapy has been previously unsuccessful in treating brain cancers such as medulloblastoma.
Description
Researchers at the University of Pittsburgh have identified eight human antibody heavy chain variable domains that have strong immunotherapeutic potential for treating medulloblastoma. These antibodies act against the oncogenic protein, protogenin. The eight identified antibody heavy chain variable domains act against different immunoglobulin and fibronectin domains of protogenin to block protogenin affected growth of medulloblastomas. These antibodies have been applied in vitro and have been shown to reduce the growth of group 3 medulloblastomas. The strong activity of these antibodies against protogenin makes them a promising immunotherapy target for treating medulloblastoma.
Applications
• Eight human antibodies that are promising immunotherapy targets for treating medulloblastoma
Advantages
• Eight human antibodies that are promising immunotherapy targets for treating medulloblastoma
Invention Readiness
In vitro
IP Status
https://patents.google.com/patent/WO2023081266A2
